From being a promising yet underexplored approach in the 1990s, mRNA therapeutics have evolved dramatically. The discovery of ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on PepGen Inc. (PEPG – Research Report) today and set a price target of $17.00.

"Imvax secures $29m to support Phase IIb glioblastoma therapy trial" was originally created and published by Clinical Trials ...

PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...

Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic ...

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...